Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.

St-Pierre J, Klein J, Choi NK, Fear E, Pannain S, Rubin DT

Digestive diseases and sciences8 Nov 2024Cited by 13 (Europe PMC)

PMID39516435DOI10.1007/s10620-024-08720-2PepBankPUB-39516435

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone16

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, BMI fell with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, BMI fell after starting semaglutide or tirzepatide (results not split by drug).
Peptide
Semaglutide
Outcome
DecreaseBMI change
Study
n = 36
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
BMI median
34 kg/m2
before
BMI median
31 kg/m2
after
Source sentences
Summary
BMI significantly decreased from 34.0 (IQR 31.0-38.2) to 31.0 (IQR 29.0-36.1) with GLP-1-based therapy (p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3951643501
02HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, total body weight fell with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, body weight fell after starting semaglutide or tirzepatide (results not split by drug).
Peptide
Semaglutide
Outcome
DecreaseTotal body weight change
Study
n = 36
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
TBW median change
8.15 kg
pooled
Source sentences
Summary
Total body weight (TBW) significantly decreased by a median of 8.15 kg (IQR 15.9-2.2 kg; p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3951643502
03HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, BMI fell with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, BMI fell after starting semaglutide or tirzepatide (results not split by drug).
Peptide
Tirzepatide
Outcome
DecreaseBMI change
Study
n = 36
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
BMI median
34 kg/m2
before
BMI median
31 kg/m2
after
Source sentences
Summary
BMI significantly decreased from 34.0 (IQR 31.0-38.2) to 31.0 (IQR 29.0-36.1) with GLP-1-based therapy (p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3951643509
04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, total body weight fell with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, body weight fell after starting semaglutide or tirzepatide (results not split by drug).
Peptide
Tirzepatide
Outcome
DecreaseTotal body weight change
Study
n = 36
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Measurements
TBW median change
8.15 kg
pooled
Source sentences
Summary
Total body weight (TBW) significantly decreased by a median of 8.15 kg (IQR 15.9-2.2 kg; p < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3951643510
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, total cholesterol showed no significant change with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, cholesterol did not change significantly with semaglutide or tirzepatide (results not split by drug).
Peptide
Semaglutide
Outcome
No significant changeTotal cholesterol change
Study
n = 36
Outcome group
Lipids · Metabolic and weight
Measurements
p
0.0634
total cholesterol
Source sentences
Summary
Although a decrease in total cholesterol and glycated hemoglobin was seen, this was not statistically significant (p = 0.0634 for total cholesterol, p = 0.0536 for glycated hemoglobin).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3951643503
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, glycated hemoglobin showed no significant change with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, HbA1c did not change significantly with semaglutide or tirzepatide (results not split by drug).
Peptide
Semaglutide
Outcome
No significant changeGlycated hemoglobin change
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Measurements
p
0.0536
glycated hemoglobin
Source sentences
Summary
Although a decrease in total cholesterol and glycated hemoglobin was seen, this was not statistically significant (p = 0.0634 for total cholesterol, p = 0.0536 for glycated hemoglobin).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3951643504
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, ALT showed no significant change with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, ALT did not change significantly with semaglutide or tirzepatide (results not split by drug).
Peptide
Semaglutide
Outcome
No significant changeALT change
Study
n = 36
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
No significant changes were observed in ALT or CRP levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3951643505
08HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, CRP showed no significant change with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, CRP did not change significantly with semaglutide or tirzepatide (results not split by drug).
Peptide
Semaglutide
Outcome
No significant changeCRP change
Study
n = 36
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
No significant changes were observed in ALT or CRP levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3951643506
09HumanNot a test of Semaglutide aloneObservational studySafety outcome
In non-diabetic adults with IBD, nausea was the most common side effect of GLP-1-based therapy (semaglutide or tirzepatide pooled), at 31%.
In plain wordsIn adults with IBD and no diabetes, nausea was the most common side effect of semaglutide or tirzepatide, in 31% (results not split by drug).
Peptide
Semaglutide
Outcome
Not applicableNausea
Study
n = 36
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Nausea
31%
pooled
Source sentences
Summary
The most common side effects were nausea (31%) and constipation (25%).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3951643507
10HumanNot a test of Semaglutide aloneObservational studySafety outcome
In non-diabetic adults with IBD, constipation was a common side effect of GLP-1-based therapy (semaglutide or tirzepatide pooled), at 25%.
In plain wordsIn adults with IBD and no diabetes, constipation was a common side effect of semaglutide or tirzepatide, in 25% (results not split by drug).
Peptide
Semaglutide
Outcome
Not applicableConstipation
Study
n = 36
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Constipation
25%
pooled
Source sentences
Summary
The most common side effects were nausea (31%) and constipation (25%).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3951643508
11HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, total cholesterol showed no significant change with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, cholesterol did not change significantly with semaglutide or tirzepatide (results not split by drug).
Peptide
Tirzepatide
Outcome
No significant changeTotal cholesterol change
Study
n = 36
Outcome group
Lipids · Metabolic and weight
Measurements
p
0.0634
total cholesterol
Source sentences
Summary
Although a decrease in total cholesterol and glycated hemoglobin was seen, this was not statistically significant (p = 0.0634 for total cholesterol, p = 0.0536 for glycated hemoglobin).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3951643511
12HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, glycated hemoglobin showed no significant change with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, HbA1c did not change significantly with semaglutide or tirzepatide (results not split by drug).
Peptide
Tirzepatide
Outcome
No significant changeGlycated hemoglobin change
Study
n = 36
Outcome group
Glycemic control · Metabolic and weight
Measurements
p
0.0536
glycated hemoglobin
Source sentences
Summary
Although a decrease in total cholesterol and glycated hemoglobin was seen, this was not statistically significant (p = 0.0634 for total cholesterol, p = 0.0536 for glycated hemoglobin).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3951643512
13HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, ALT showed no significant change with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, ALT did not change significantly with semaglutide or tirzepatide (results not split by drug).
Peptide
Tirzepatide
Outcome
No significant changeALT change
Study
n = 36
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
No significant changes were observed in ALT or CRP levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3951643513
14HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome
In non-diabetic adults with IBD, CRP showed no significant change with GLP-1-based therapy (semaglutide or tirzepatide pooled).
In plain wordsIn adults with IBD and no diabetes, CRP did not change significantly with semaglutide or tirzepatide (results not split by drug).
Peptide
Tirzepatide
Outcome
No significant changeCRP change
Study
n = 36
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
No significant changes were observed in ALT or CRP levels.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3951643514
15HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In non-diabetic adults with IBD, nausea was the most common side effect of GLP-1-based therapy (semaglutide or tirzepatide pooled), at 31%.
In plain wordsIn adults with IBD and no diabetes, nausea was the most common side effect of semaglutide or tirzepatide, in 31% (results not split by drug).
Peptide
Tirzepatide
Outcome
Not applicableNausea
Study
n = 36
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Nausea
31%
pooled
Source sentences
Summary
The most common side effects were nausea (31%) and constipation (25%).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3951643515
16HumanNot a test of Tirzepatide aloneObservational studySafety outcome
In non-diabetic adults with IBD, constipation was a common side effect of GLP-1-based therapy (semaglutide or tirzepatide pooled), at 25%.
In plain wordsIn adults with IBD and no diabetes, constipation was a common side effect of semaglutide or tirzepatide, in 25% (results not split by drug).
Peptide
Tirzepatide
Outcome
Not applicableConstipation
Study
n = 36
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Measurements
Constipation
25%
pooled
Source sentences
Summary
The most common side effects were nausea (31%) and constipation (25%).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a single-center observational cohort study that included adult patients with IBD who were started on GLP-1-based therapy (semaglutide or tirzepatide) for weight loss from January 2021 to April 2024.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3951643516

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.